Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC
Michael Michael, Shane C White, Ehtesham Abdi, Louise Nott, Phillip Clingan, Allan Zimet, Peter Button, Daniel Gregory, Benjamin Solomon, Alexander Dobrovic, Hongdo Do, Stephen Clarke
Asia-Pacific Journal of Clinical Oncology | WILEY | Published : 2015
The GATE study was sponsored by Roche Products, Pty Limited, Australia. The authors would like to thank all study investigators, coordinators and patients who participated in the study. We would also like to thank the Roche study team. Medical writing assistance was provided by Dr Joseline Ojaimi from Roche Products.